key: cord-0850273-nmb7x114
authors: Mirmosayyeb, Omid; Vaheb, Saeed; Barzegar, Mahdi; Shaygannejad, Vahid; Bonavita, Simona; Ghajarzadeh, Mahsa
title: Screening neuromyelitis optica patients for COVID-19 infection
date: 2020-09-14
journal: Autoimmun Rev
DOI: 10.1016/j.autrev.2020.102669
sha: f856d3e86b9bf774e7b81cb2dc54afab7e48d4b8
doc_id: 850273
cord_uid: nmb7x114

nan

The link was sent to 200 NMO patients and finally 157 filled forms were gathered. Mean age and mean disease duration were 38±10.8 and 6±4 years, respectively. One hundred and twenty-five were female (79.8%) and 50.3%

were treated with Rituximab and 49.7% with Azathioprine. The most common symptoms were myalgia, and headache/vertigo. 

Demographic and clinical features of neuromyelitis optica: a review

Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Rituximab does not reset defective early B cell tolerance checkpoints

Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability